Gov. Hogan visits Montgomery County business
Monday he visited Novavax, a company that makes vaccines
By Kylie Khan | firstname.lastname@example.org
Published 07/18 2016 07:28PMUpdated 07/18 2016 07:28PM
Maryland's Governor Larry Hogan was not at the Republican National Convention Monday.
Instead he was in Montgomery County. One stop on his agenda included a vaccine company called Novavax. Novavax started with about 100 employees in 2011, and today they've grown to more than 500.
The company is quickly expanding and working on several vaccines to treat viruses like Ebola and Zika.
Governor Hogan says Montgomery County helps drive the economy in Maryland and work done at Novavax will solve problems worldwide.
"The work that they're doing, not only does it add to our economy here in Maryland and put a lot of people to work, but it's really going to be saving lives around the world. We're very proud of having them in our state," Gov Hogan said.
Novavax was also named one of the top places to work by the Washington Post.
8-11-15 Blast From Past
Novavax shares ($NVAX) surged today on the news that its vaccine for respiratory syncytial virus (RSV) proved effective in a large midstage study that company officials billed as a "historic" achievement.
Long an elusive goal in development circles after inactivated vaccines proved dangerous in the '60s, Novavax is angling to launch a late-stage program for the RSV vaccine later in the year, company execs tell Bloomberg. And CEO Stanley Erck previewed the company's blockbuster commercial expectations with Reuters yesterday, telling the news service that it could be "the largest selling vaccine in the history of vaccines in terms of revenue."
That may be, but the vaccine provided significantly less than universal protection against the virus, which is a mortal threat to a host of infants and the elderly every year. Investigators for Novavax noted that the big Phase II study demonstrated that their vaccine was 46% effective in preventing lower respiratory tract infections and 44% effective against all symptoms of RSV disease.
The company's stock jumped about 10% on the news, which was timed to coincide with Novavax's quarterly report.
Bolstered with $1 billion peak sales projections in the U.S. alone, Novavax isn't tempering the hype around this program.
"These efficacy data represent a historic advance for the field," said Novavax R&D chief Gregory Glenn in a statement. "This is also an important confirmation of the burden of RSV disease in older adults and highlights the high rate of lower respiratory tract symptoms in those infected by RSV in a large, prospective trial. It is clear that our RSV F Vaccine provided statistically significant efficacy in older adults, a population that historically has been difficult to protect. The reduction in symptomatic RSV, RSV with lower respiratory tract illness and RSV associated with difficulty breathing are breakthrough results."
"It could be a major breakthrough," Andrew Pavia, a spokesman for the Infectious Diseases Society of America, tells the AP. But he adds that these results need to be confirmed in Phase III before the celebrations can begin. "It's not time to break out the champagne."
A big market awaits Novavax if it proves successful. The CDC notes that with no vaccine to stop infection, 100,000 infants are hospitalized each year, with 177,000 hospitalizations and 14,000 deaths among adults over 65.
It's not unusual for a vaccine to provide significantly less than universal protection, but with fewer than half of the population protected against the common virus, Novavax still has some major league competition to consider.
Moncef Slaoui, who was moved from head of R&D at GlaxoSmithKline ($GSK) to chief of the enlarged vaccines business--which swelled with a vaccine/cancer drug portfolio flip with Novartis ($NVS)--recently noted that their RSV vaccine had completed Phase I and was headed into a Phase II among pregnant women. Novartis also cleared early studies with their vaccine and then presumably handed it over to GSK. AstraZeneca's ($AZN) MedImmune, a neighbor of Novavax in Rockville, MD, won fast-track status for their early-stage effort last spring. And Bavarian Nordic has reviewed its own preclinical results in RSV.
Vaccine development tends to be fast during an epidemic and a grinding, slow slog otherwise. But with Novavax taking the lead in such a big field, with global implications, regulators are more likely to provide an assist in getting this vaccine through Phase III at a more rapid pace.
- here's the release
- here's the AP report
The net after tax proceeds of the transaction received by GSK today are estimated to be $7.8 billion. This reflects the full consideration of $16 billion paid today by Novartis for GSK’s Oncology portfolio and related assets. Under the terms of the transaction, up to $1.5 billion of that purchase price may have to be returned to Novartis if certain conditions relating to the COMBI-d Trial are not met. Following the positive results from this study announced on 6 February 2015, GSK believes these conditions will be satisfie.
Proceeds after the trade to Novartis
Gsk gets 7.8 billion dollars
GSK/Novartis transaction | GSK
GSK › en-gb › Media
Mobile-friendly - On 28 January 2015, we announced that our major three-part transaction with Novartis has completed. As a result, GSK has acquired Novartis’s global Vaccines business (excluding influenza vaccines), created a new world-leading Consumer Healthcare joint venture with Novartis and ..
Call sellers are short
If they sell you a call that expects the price to rise to 10 . From present 7.4
And if they are sure it wont.
And if the price doesnt
You bought junk. They collected on a sure thing
Same with puts in teverse. But calls are easier to explain
And if they are very sure the price wont rise. The can sell a lot of cheap calls. And still make a killing
Same with puts
But who can be sure? Yes, who can be sure. Who
Yeah that must be it. If the transcript is correct
What made it stick in my mind was how quickly after Stan said the 3rd qtr, the analyst chimed in with
early August. It was in his mind. Like he was correcting Stan.
That's his business. He was sure.
If you were asking an expert (Stan) a question, then correct the experts answer
That made it stand out
When writing put options, the investor who is short is betting that the stock price will remain above the exercise price during the term of the option. When this happens, the investor is able to keep the premium and earn income from the strategy
Read more: Three Ways to Profit Using Put Options | Investopedia http://www.investopedia.com/articles/active-trading/070814/three-ways-profit-using-put-options.asp#ixzz4FEokTcaJ
Follow us: Investopedia
THE LAST-MINUTE DECISION to include in the Republican platform a call to restore the firewall between commercial and investment banking comes as a surprise, because Donald Trump himself has never publicly addressed or endorsed such a reform in his year-long presidential run.
To the extent that Trump has expressed anything about financial reform, it’s been a desire to roll it back. He told The Hill last October that the Dodd-Frank law is “terrible” and “the regulators are running the banks.” Dodd-Frank’s repeal is also in the Republican platform.
TapImmune? Partnership with AZN. NEW YORK, NY / ACCESSWIRE / April 26, 2016 / AstraZeneca (AZN), a big pharma leader in immuno-oncology has placed its bets on a cancer vaccine technology from TapImmune (TPIV). Amongst a bevy of partnerships, collaborations, and M&A activity between big pharma and innovative biotechs focused on immunotherapies that treat cancer, TapImmune is getting much deserved attention from its bigger brethren looking to fill their pipelines with the most promising cancer cures.
A joint AstraZeneca-TapImmune Phase 2 ovarian cancer trial will start this quarter at the prestigious Sloan Kettering Institute, according to a press release issued a few days ago. The trial will test a combination therapy which includes TapImmune's TPIV 200, a T-cell cancer vaccine, with AstraZeneca's durvalumab an anti-PD-L1 antibody, in 40 women who have high-grade ovarian cancer and have not been responsive to platinum chemotherapy, currently the standard of care for advanced ovarian cancer
This is new information for me!
Morec70 plus could mean more deaths
And it could be spun either way
They are older so its expected
Or, despite that they were selected because of their health and they died anyway
But still with all of the p1,p2,p2booster, p3 it will be hard for manipulators to spread doubt,
But good ole Ted Tentoff could get creative.
The suprise is that even tho high titers are more difficult in 70+
If they come out as high as 60+, thats very good? Correct?
And this is the first time for 70 plus
Please pay attentio
Nobody can catch all the fluctuations. In a bull market your game is to buy and hold until you believe that the bull market is near its end. To do this you must study general conditions and not tips or special factors affecting individual stocks. Then get out of all your stocks; get out for keeps! Wait until you see-or if you prefer, until you think you see-the turn of the market
This is from a book about Larry Livermore
He says you must study general conditions and not tips and special factors affecting individual stocks
Then he goes on to explain how he made money after reading about the 1906 San Francisco earthquake
When will the general condition of BLM and ISSA begin to affect the general market?
7. We already have licensing, registration, titles, inspection, and multiple taxes on large commercial vehicles, and STILL they are used for mass killing. Enough is enough. We must ban them entirely.